Jiangsu Bioperfectus Technologies Co., Ltd. announcement, the closing price of the company's stock has deviated by 30% consecutively for three trading days, indicating abnormal stock trading fluctuations. After the company's self-inspection and inquiries to the controlling shareholder and actual controller, as of October 8, 2024, there is no significant undisclosed information that should have been disclosed. The company's current operational activities are all normal, and there have been no major adjustments in market conditions or industry policies.